Total neoadjuvant FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy and adjuvant gemcitabine for resectable and borderline resectable pancreatic cancer (PREOPANC-2 trial): study protocol for a nationwide multicenter randomized controlled trial

Abstract Background Neoadjuvant therapy has several potential advantages over upfront surgery in patients with localized pancreatic cancer; more patients receive systemic treatment, fewer patients undergo futile surgery, and R0 resection rates are higher, thereby possibly improving overall survival...

Ausführliche Beschreibung

Bibliografische Detailangaben

Hauptverfasser:	Q. P. Janssen, J. L. van Dam, B. A. Bonsing, H. Bos, K. P. Bosscha, P. P. L. O. Coene, C. H. J. van Eijck, I. H. J. T. de Hingh, T. M. Karsten, M. B. van der Kolk, G. A. Patijn, M. S. L. Liem, H. C. van Santvoort, O. J. L. Loosveld, J. de Vos-Geelen, B. M. Zonderhuis, M. Y. V. Homs, G. van Tienhoven, M. G. Besselink, J. W. Wilmink, B. Groot Koerkamp, for the Dutch Pancreatic Cancer Group
Format:	Artigo
Sprache:	Inglês
Veröffentlicht:	BMC 2021-03-01
Schriftenreihe:	BMC Cancer
Schlagworte:	Neoadjuvant FOLFIRINOX Gemcitabine Chemoradiotherapy Localized pancreatic cancer Intention-to-treat
Online-Zugang:	https://doi.org/10.1186/s12885-021-08031-z
Tags:	Tag hinzufügen Keine Tags, Fügen Sie das erste Tag hinzu!